Outset Medical
114 hedge funds and large institutions have $113M invested in Outset Medical in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 35 closing their positions.
58% more call options, than puts
Call options by funds: $575K | Put options by funds: $363K
0.89% less ownership
Funds ownership: 7.55% → 6.67% (-0.89%)
19% less funds holding
Funds holding: 140 → 114 (-26)
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
63% less capital invested
Capital invested by funds: $308M → $113M (-$195M)
71% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$7.19M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$4.19M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.88M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.07M |
| 5 |
Millennium Management
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$17.1M |
| 2 |
Morgan Stanley
New York
|
-$12.6M |
| 3 |
JP Morgan Chase
New York
|
-$6.23M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$4.01M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.54M |
OM Hedge Fund Activity: Q1 2024 in Review
114 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q1 2024, worth a combined $113M — down 63% from $308M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of OM and 10 opened new positions — a net loss of 25 holders — while 42 trimmed existing stakes and 33 added.
The largest buyer was Ameriprise, adding an estimated $7.19M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $17.1M sold.
- 114 institutional investors held Outset Medical (OM) as of Q1 2024, down from 140 in Q4 2023.
- Funds reported $113M of Outset Medical stock for Q1 2024, down 63% quarter-over-quarter.
- 10 funds opened new Outset Medical positions in Q1 2024 and 35 closed out, a net change of -25 holders.
- The largest Outset Medical buyer in Q1 2024 was Ameriprise, an estimated $7.19M added.
- The largest Outset Medical seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q1 2024.